AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26481067
Drug: Prophylactic intra-abdominal
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic intra-abdominal drainage following rectal resection
Trial: 26482301
Drug: Rifabutin treatment
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifabutin treatment
Trial: 26482312
Drug: Telavancin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telavancin (10 mg/kg/day for CLCR >50 ml/min; 7.5 mg/kg/day for CLCR 30-49 ml/min)
Trial: 26482376
Drug: Sodium tanshinone
RxNorm normalized name: Tanshinone I
DrugBank: Tanshinone I (DB16886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium tanshinone IIA sulfonate (80 mg q.d. for 7 days) in addition to standard therapy
Trial: 26482895
Drug: Renal sympathetic
RxNorm normalized name: Bos taurus sympathetic nerve preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal sympathetic denervation (RSD) via endovascular radiofrequency ablation (RFA) of the renal arteries, with continued full-dose antihypertensive therapy (4.1 drugs) including diuretics.
Trial: 26483108
Drug: Statin-based LDL-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin-based LDL-C lowering therapy
Trial: 26483516
Drug: Telaprevir-based therapy
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telaprevir-based therapy (750 mg every 8 hours, 1125 mg if on efavirenz) plus Peg-IFNα2a (180 μg/week) and ribavirin (800 mg/day) for 12 weeks, followed by Peg-IFNα2a and ribavirin alone for 12 or 36 weeks depending on patient type.
Trial: 26483516
Drug: Telaprevir-based therapy
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telaprevir-based therapy
Trial: 26486517
Drug: Tariquidar (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tariquidar (2 mg/kg)
Trial: 26486517
Drug: Tariquidar in
RxNorm normalized name: Tariquidar
DrugBank: Tariquidar (DB06240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tariquidar in combination with docetaxel
Trial: 26486517
Drug: Tariquidar in
RxNorm normalized name: Tariquidar
DrugBank: Tariquidar (DB06240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tariquidar in combination with vinorelbine
Trial: 27581680
Drug: Pitavastatin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin (4 mg/day) for 180 days
Trial: 26488691
Drug: Total knee
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total knee replacement followed by 12 weeks of nonsurgical treatment
Trial: 26488691
Drug: Nonsurgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsurgical treatment alone
Trial: 26488758
Drug: Preoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiation therapy (specific dosage not mentioned)
Trial: 26490100
Drug: Osmolarity equation:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osmolarity equation: osmolarity=1.86×(Na++K+)+1.15×glucose+urea+14 (all measured in mmol/L)
Trial: 26490103
Drug: Agalsidase-beta (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agalsidase-beta (1 mg/kg/2 weeks) with antiproteinuric therapy (ACE inhibitors or ARBs)
Trial: 26490491
Drug: Hunger ratings
RxNorm normalized name: Aratinga erythrogenys feather extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hunger ratings recorded twice daily (both P = 0.02)
Trial: 26490491
Drug: Fasting plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting plasma concentrations of insulin increased by 120% ± 15% (P = 0.02)
Trial: 26490645
Drug: Orbital Atherectomy
RxNorm normalized name: barbital
DrugBank: Barbital (DB01483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orbital Atherectomy System (OAS) followed by adjunctive balloon angioplasty (BA)
Trial: 26491799
Drug: Erythropoietin administration
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin administration and transfusion threshold
Trial: 26492842
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of phonation and reflux events
Trial: 26492847
Drug: Lactulose challenge
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lactulose challenge test (25 g lactulose in a liquid breakfast of 400 mL Nutridrink)
Trial: 26492921
Drug: Modified sham
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified sham feeding (MSF) with atropine (1 mg bolus 45 min before MSF + 80 ng·kg(-1)·min(-1) for 2 h)
Trial: 26496767
Drug: Pegvisomant (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegvisomant (single dose)
Trial: 26497198
Drug: Decitabine 5
RxNorm normalized name: decitabine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decitabine 5 mg/m(2)/day for 5 consecutive days with 4-week intervals, individualized doses for Cycles 2 to 4 based on pharmacokinetic-pharmacodynamic modeling.
Trial: 26497198
Drug: Decitabine (individualized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decitabine (individualized doses for Cycles 2 to 4)
Trial: 26497198
Drug: Initial doses
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial doses for cohorts 2 to 5 were 4, 5, 5.5, and 5 mg/m(2)/day, respectively; median maintenance dose was 7 mg/m(2)/day.
Trial: 26499927
Drug: Plasma levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma levels of galectin-9 above 690 pg/mL
Trial: 26499927
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of galectin-9 level and Model For End-Stage Liver Disease score
Trial: 26500339
Drug: Sequential scheme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential scheme (9 cycles of VMP followed by 9 cycles of Rd; n = 118)
Trial: 26500339
Drug: Sequential scheme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential scheme
Trial: 26503201
Drug: Radiotherapy (RT)
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy (RT) doses of greater than 80.5 Gy (median, 58.05 Gy)
Trial: 26503201
Drug: Radiotherapy (RT)
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy (RT) doses of lower than 80.5 Gy
Trial: 26503201
Drug: Radiotherapy (RT)
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy (RT) doses of greater than 80.5 Gy
Trial: 26503811
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (r-hGH)
Trial: 26504182
Drug: Sirolimus as
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus as monotherapy
Trial: 26506438
Drug: 13-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13-valent pneumococcal conjugate vaccine (PCV-13)
Trial: 26507836
Drug: KHK2866 (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KHK2866 (0.3, 1, and 3 mg/kg) intravenously once weekly
Trial: 26507836
Drug: KHK2866 (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KHK2866 (0.1 mg/kg)
Trial: 26507836
Drug: KHK2866 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KHK2866 (all doses)
Trial: 26508138
Drug: Tramadol (200-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (200-mg extended-release tablets)
Trial: 26508901
Drug: Chemotherapy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy without ifosfamide/etoposide
Trial: 26508901
Drug: Age, treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age, treatment, tumor location, and tumor size
Trial: 26509071
Drug: Corticosteroids >5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids >5 mg/day
Trial: 26509071
Drug: Corticosteroids ≤5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids ≤5 mg/day
Trial: 26509071
Drug: Continued corticosteroid
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued corticosteroid treatment
Trial: 26510696
Drug: Warfarin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin treatment (mean duration 1 year, mean INR 1.9 for IPAH, 2.0 for SSc-PAH)
Trial: 26510696
Drug: Warfarin-naïve patients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin-naïve patients (matched control group)
Trial: 26511221
Drug: Novel oral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel oral anticoagulants (NOACs) administered intermittently based on ICM guidance
Trial: 26511221
Drug: Intermittent NOAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent NOAC administration
Trial: 26511652
Drug: Fluorinated (19F)
RxNorm normalized name: fluorine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorinated (19F) agent CS-1000 labeled SVF cells
Trial: 26511835
Drug: Wood smoke
RxNorm normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wood smoke exposure (PM1 concentration at 314 μg/m(3) for 3 hours)
Trial: 26512876
Drug: Continuous afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Continuous afatinib 30 mg plus nintedanib 150 mg
Trial: 26512876
Drug: Intermittent afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intermittent afatinib 40 mg plus nintedanib 150 mg
Trial: 26514315
Drug: Fostamatinib 100
RxNorm normalized name: fostamatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostamatinib 100 mg BID co-administered with digoxin 0.25 mg once daily on days 9 to 15
Trial: 26514315
Drug: Digoxin 0.25
RxNorm normalized name: digoxin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin 0.25 mg BID on day 1 and 0.25 mg once daily on days 2 to 8
Trial: 26514334
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (splenectomy and SAE)
Trial: 26514420
Drug: Vaccine alone
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine alone (10 μg dLPS)
Trial: 26514420
Drug: Vaccine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine plus CPG 7909 (250 or 500 μg)
Trial: 26514928
Drug: Behavioral support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral support techniques (preparation, distraction, coaching, reinforcement) during in-office tympanostomy tube placement
Trial: 26515198
Drug: Recombinant tissue-type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant tissue-type plasminogen activator (r-tPA) treatment
Trial: 26515457
Drug: Once-daily Basal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily Basal Insulin (BI) therapy in the morning
Trial: 26515457
Drug: Once-daily Basal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily Basal Insulin (BI) therapy
Trial: 26518132
Drug: 14-day treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14-day treatment (T14) with chloroquine (CQ) for 3 days (10, 10, and 5 mg/kg) and primaquine (PQ) daily for 14 days (0.25 mg/kg)
Trial: 26518132
Drug: Intermittent single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent single dose (ISD) regimen with a single dose of CQ (10 mg/kg) and PQ (0.75 mg/kg) on days 0, 30, 60, 180, 210, and 240
Trial: 26518132
Drug: 14-day treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14-day treatment (T14)
Trial: 26518736
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of three neuropsychological tests (five-word, cognitive disorders examination, verbal fluency)
Trial: 26518979
Drug: Lamotrigine (LTG)
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine (LTG) monotherapy at an initial dose of 0.3 mg/kg/day for 2 weeks, followed by 0.6 mg/kg/day for an additional 2 weeks, then increased by 0.6 mg/kg/day up to a maximum of 10.2 mg/kg/day or 400 mg/day until seizure free confirmed by HV-EEG.
Trial: 26518979
Drug: Lamotrigine (LTG)
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine (LTG) monotherapy during the 12-week maintenance phase.
Trial: 26518979
Drug: Lamotrigine (LTG)
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine (LTG) monotherapy.
Trial: 30773100
Drug: Omega-3 PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 PUFA supplementation (4 g of eicosapentaenoic acid and docosahexaenoic acid daily)
Trial: 26525052
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (DEX) infusion at a dose of 0.2-1.4 μg/kg/h with symptom-triggered benzodiazepine (10 mg diazepam bolus) as needed
Trial: 26525052
Drug: Symptom-triggered 10
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom-triggered 10 mg boluses of diazepam only
Trial: 26526721
Drug: CD133+ autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD133+ autologous stem cells administered intramuscularly
Trial: 26526971
Drug: Lacosamide (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacosamide (up to 400 mg)
Trial: 26526984
Drug: Galunisertib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galunisertib (80 mg, Cohort-1)
Trial: 26526984
Drug: Galunisertib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galunisertib (150 mg, Cohort-2)
Trial: 26527676
Drug: Change in
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change in the Functional Assessment of Cancer Therapy-Bone Marrow Transplant score
Trial: 26528503
Drug: Standard contrast-assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard contrast-assisted cannulation (CC)
Trial: 26529118
Drug: Nortriptyline 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline 100 mg
Trial: 26529238
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of AERAS-402 followed by MVA85A
Trial: 26529238
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of AERAS-402
Trial: 26531748
Drug: Standard primary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard primary treatment according to the stage of disease
Trial: 26535053
Drug: Self-administered acupressure
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered acupressure for 10 days
Trial: 26535134
Drug: Tabalumab 120
RxNorm normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tabalumab 120 mg every 4 weeks (120/Q4W)
Trial: 26535134
Drug: Tabalumab 90
RxNorm normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tabalumab 90 mg every 2 weeks (90/Q2W)
Trial: 26535135
Drug: Etanercept (ETN)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (ETN) 50 mg plus Methotrexate (MTX) for 52 weeks
Trial: 26535146
Drug: Delayed-release (DR)
RxNorm normalized name: Delayed Release Oral Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release (DR) prednisone 5 mg once daily for 12 weeks
Trial: 26536893
Drug: Triheptanoin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triheptanoin treatment
Trial: 26537529
Drug: Bosutinib 500
RxNorm normalized name: bosutinib 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosutinib 500 mg/day
Trial: 26537623
Drug: Romiplostim (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romiplostim (starting dose of 1 μg/kg)
Trial: 26537623
Drug: Romiplostim (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romiplostim (after discontinuation)
Trial: 26537623
Drug: Romiplostim (during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romiplostim (during treatment)
Trial: 26537851
Drug: Allogeneic bone
RxNorm normalized name: Human allogeneic bone marrow derived osteoblastic cells
DrugBank: Human allogeneic bone marrow derived osteoblastic cells (DB17890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic bone marrow derived MSCs, 1.5 × 10(6) per kg body weight, administered intravenously at 25 and 26 weeks after transplantation.
Trial: 26539981
Drug: Rituximab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (1 g at D0, D15, and M6)
Trial: 26541511
Drug: Ipilimumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (3 mg/kg, up to four cycles, administered in 3 week intervals)
Trial: 26542378
Drug: ONO/GS-4059 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO/GS-4059 (20 mg to 600 mg once daily, with twice-daily regimens of 240 mg and 300 mg)
Trial: 26543510
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg daily oral pioglitazone for 28 days
Trial: 26543765
Drug: Schedule A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule A: 3-weekly epirubicin (90 mg/m2) and docetaxel (75 mg/m2) chemotherapy
Trial: 26543765
Drug: Schedule B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule B: 2-weekly epirubicin (60 mg/m2) and docetaxel (60 mg/m2) chemotherapy
Trial: 26545441
Drug: Ceftaroline fosamil
RxNorm normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftaroline fosamil 200 mg 1-h i.v. infusion post-haemodialysis
Trial: 26545441
Drug: Ceftaroline fosamil
RxNorm normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftaroline fosamil 600 mg 1-h i.v. infusion in healthy volunteers
Trial: 26545441
Drug: Ceftaroline fosamil
RxNorm normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftaroline fosamil 200 mg 1-h i.v. infusion pre-haemodialysis
Trial: 26545441
Drug: Ceftaroline fosamil
RxNorm normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftaroline fosamil 200 mg 1-h i.v. infusion (pre- and post-haemodialysis)
Trial: 26545911
Drug: Thrombophilic SNPs
RxNorm normalized name: SNP-ACTH (1-39)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombophilic SNPs (factor V Leiden, H1299R, prothrombin G20210A, factor XIII V34L, β-fibrinogen -455G → A, plasminogen activator inhibitor-1 4G/5G, human platelet antigen-1 a/b9L33P, methylenetetrahydrofolate reductase C677T and A1298C)
Trial: 26547188
Drug: Helical IMRT
RxNorm normalized name: Ep-100 (conjugate of luteinizing hormone-releasing hormone with a cationic .alpha.-helical peptide for therapy of lhrh-expressing tumors)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helical IMRT of the pelvic lymph nodes (51.0 Gy) with a simultaneous integrated boost to the prostate (76.5 Gy) in 34 fractions, following at least two months of antihormonal treatment before radiotherapy continuing for at least 2 years.
Trial: 26547914
Drug: Transdermal buprenorphine
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Transdermal buprenorphine (TDB) patches (5-20 μg/h and 35-70 μg/h)
Trial: 26552042
Drug: WEB treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WEB treatment with antiplatelet agents
Trial: 26554651
Drug: Eribulin mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin mesylate and gemcitabine (1.0 mg/m² eribulin and 1000 mg/m² gemcitabine on days 1 and 8 of a 28-day cycle)
Trial: 26556899
Drug: Blood urea
RxNorm normalized name: BLOOD UREA NITROGEN TEST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood urea nitrogen level >8.2 mmol/L
Trial: 26556899
Drug: Hemoglobin level
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin level <75 g/L
Trial: 26556899
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of all 3 risk factors (blood urea nitrogen >8.2 mmol/L, hemoglobin <75 g/L, muscle strength ≤3)
Trial: 26557215
Drug: Twice-daily regimen
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily regimen of cleanser (7.8% 1-lactic acid, 2% salicylic acid) and anti-aging serum (0.1% alpha hydroxy acids-retinoids, 6.5% 1-lactic acid) with concurrent use of sun protection factor 50+ sunscreen as needed